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Eukaryotic initiation factor eIF4E and its phosphorylation play key roles in cell transformation and
tumorigenesis. eIF4E is phosphorylated by the Mnks (MAP (mitogen-activated protein) kinase-inter-
acting kinases). Rapamycin increases eIF4E phosphorylation in cancer cells, potentially limiting
their anti-cancer effects. Here we show that the rapamycin-induced increase in eIF4E phosphoryla-
tion reﬂects increased activity of Mnk2 but not Mnk1. This activation requires a novel phosphoryla-
tion site in Mnk2a, Ser437. Our ﬁndings have potentially important implications for the use of
rapamycin and its analogues in cancer therapy, suggesting that inhibitors of mTOR and Mnk (or
Mnk2) may be more efﬁcacious than rapalogs alone.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Eukaryotic initiation factor 4E (eIF4E) binds to the 50-cap struc-
ture of eukaryotic mRNAs. eIF4E also interacts with the scaffold
protein eIF4G to recruit other translation factors and the 40S ribo-
somal subunit to the mRNA, to facilitate efﬁcient initiation of
mRNA translation. eIF4E is strongly implicated in events that lead
to tumorigenesis; e.g., levels of eIF4E are elevated in many cancers
(reviewed [1,2]) and artiﬁcial overexpression of eIF4E in mamma-
lian cells [3] or in animal models leads to transformation or accel-
erated tumorigenesis [4,5]. This may be because increasing the
levels of available eIF4E favours the translation or nucleocytoplas-
mic transport of certain mRNAs, whose products promote cell pro-
liferation or survival [6].
eIF4E availability is restricted by its association to eIF4E-bind-
ing proteins (4E-BPs) which block its binding to eIF4G; 4E-BPs
are phosphoproteins, and their phosphorylation by the mamma-
lian target of rapamycin complex 1 (mTORC1) at speciﬁc sites
causes their release from eIF4E allowing the latter to bind to eIF4G.
mTORC1 is activated downstream of signaling pathways such as
the ERK MAP kinase and protein kinase B (Akt) (reviewed [7,8]),
which include components that become oncogenic (e.g., Ras, PI
3-kinase) or are regulated by tumour suppressor proteins. Thus,
mTORC1 is hyperactive in many tumour cells, favouring activationof eIF4E. Such data have prompted numerous studies of rapamycin
and related compounds (‘rapalogs’) as anti-tumour agents, leading
to approval of certain rapalogs in advanced renal cell carcinoma
and other settings [9]. Active site-directed inhibitors of mTOR are
now available; unlike rapamycin, they inhibit all mTOR’s functions
(see e.g., [10–12]).
eIF4E is phosphorylated on Ser209 [13,14] by protein kinases
termed MAP kinase-interacting kinases (or MAP kinase-integrat-
ing kinases; Mnks). Mammals contain two Mnk genes, Mnk1
and Mnk2, which in human cells each give rise to two mRNAs
and thus two Mnk isoforms. Only the longer human Mnk iso-
forms, termed Mnk1a and Mnk2a, contain a C-terminal ERK-bind-
ing site [15,16].
Mnk1a shows low basal activity, which is markedly increased
by stimuli that activate MAP kinase signaling [17,18], whereas
Mnk2a shows high basal activity which is only slightly changed
by activating or inhibiting ERK signaling; this likely reﬂects the fact
that phosphorylated, active ERK can bind stably to Mnk2a but not
Mnk1, causing its continuous activation [19–21].
Recent data indicate that the Mnks and the phosphorylation of
eIF4E play important roles in tumorigenesis, likely by regulating
the translation of speciﬁc mRNAs [22–24]. The Mnks and eIF4E
phosphorylation may therefore play a key role in many tumours.
Considering the clear links between eIF4E phosphorylation and
tumorigenesis and the increasing use of rapalogs in cancer therapy,
it is concerning that rapamycin actually enhances eIF4E phosphor-
ylation in several cell types [25–29]. Here, we have sought to gain
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hance eIF4E phosphorylation.
2. Materials and methods
2.1. Plasmids and protein expression
Constructs encoding N-terminal HA-(hemagglutinin) tagged
Mnk2a was made by cloning a full length Mnk2a PCR digest into
the pCMV5HA vector after Hind/Xba digest. Ser437Ala mutant of
Mnk2a was generated by PCR using Phusion DNA polymerase
(Thermo Scientiﬁc). Full-length human eIF4E was cloned into a
pET28 vector from a pEE14.1 vector after NcoI–EcoRI digest. Re-
combinant eIF4E was expressed in Escherichia coli and puriﬁed as
described [30].
2.2. Cell culture and transfections
Immortalized WT (wildtype), Mnk1-KO (Mnk1/ Mnk2+/+) and
Mnk2-KO (Mnk1+/+ Mnk2/) MEFs (mouse embryonic ﬁbroblasts)
were kindly provided by Dr. Rikiro Fukunaga, Kyoto University, Ja-
pan. MEFs and PC3 cells were cultured as described [31].
PC3s were transiently transfected using polyethylenimine (PEI);
22.5 ll of PEI (HEPES–KOH, pH 7.0) was mixed with 3 lg of plas-
mid in 200 ll basal DMEM and left for 15 min at room tempera-
ture. Cells were washed twice in basal DMEM and then
incubated with 2.25 ml basal DMEM. The PEI–plasmid mix was
made up to 750 ll with complete DMEM and added dropwise toFig. 1. Effects of rapamycin on m7GTP cap-associated proteins. (A) Western blot analysis
puriﬁcations. Lysates from PC3 cells which had been starved of serum overnight and the
phosphorylated at Thr202/Tyr204 and total ERK. (B) Graphical representation of the ratio
eIF4E. In B and C, bands were quantiﬁed using the Licor Odyssey software. Student’s t-tthe cells. After 2 h, the medium was removed and replaced with
complete DMEM. PC3s were used for small interfering RNA (siRNA)
(Dharmacon) experiments using Dharmafect (Dharmacon). For siR-
NA experiments using 6-well plates, 5 ll (10 mM stock, Dharma-
con) siRNA was added to 195 ll DMEM (no additives), in a
separate tube, 5 ll Dharmafect reagent (formulation 3, Dharma-
con) was mixed with 195 ll DMEM (no additives) both tubes were
left for 5 min room temperature. The contents of the tubes were
mixed together and left for further 20 min at room temperature.
For each well, 1.6 ml DMEM (without FBS and antibiotics) was
added and mixed with the siRNA suspension. Two millilitres were
added to each well. Protein expression was assessed 48 h after
transfection.
Cells were serum starved overnight and treated as indicated
with rapamycin (100 nM); PP242, mTOR kinase inhibitor [10]
(1 lM) and phorbol myristate acetate (PMA, which stimulates pro-
tein kinase C and activates ERK) (0.5 lM).
m7GTP-Sepharose pulldowns, immunoprecipitations and Wes-
tern blotting.
After treatment cells were washed 1–3 times in 1 phosphate-
buffered saline (PBS). The desired volume of ice-cold lysis buffer
(25 mM Tris–HCl, pH 7.6, 50 mM b-glycerol phosphate, 50 mM
KCl, 1% Triton X-100, 1 mM DTT, 0.5 mM Na3VO4, and 1 protease
inhibitor cocktail [Roche]) was added and the material scraped into
a microfuge tube. Lysates were centrifuged at 16000g at 4 C for
10 min. Supernatants were transferred to newmicrofuge tubes and
lysates were either prepared for analysis or stored at 80 C. Pro-
tein concentrations were determined using the Bradford methodof eIF4E phosphorylated at Ser209, eIF4G, 4E-BP1 and eIF4E from m7GTP-Sepharose
n treated with 100 nM rapamycin or 1 lM PP242 for 2 h were also analysed for ERK
of p-eIF4E/total eIF4E. (C) Graphical representation of the ratio of total eIF4G to total
est was used to analyse the data, ⁄indicates P < 0.05 compared to control, n = 3.
Fig. 2. Mnk2 is required for rapamycin-induced phosphorylation of eIF4E. (A)
Western blot analysis of p-eIF4E and total eIF4E from m7 GTP puriﬁcations from
lysates from WT, Mnk1-KO and Mnk2-KO. Cells were treated with 100 nM
rapamycin for 2 h. The vertical lines indicate that each section contains non-
adjacent lanes which are all from the same gel and immunoblot. (B) Graphical
representation of the ratio of p-eIF4E/eIF4E expressed as % of that in untreated cells
(left side) or % of that in untreated wildtype cells (right side). Intensities were
quantiﬁed by densitometry using the Licor Odyssey software. Student’s t-test was
used to analyse the data, ⁄indicates P < 0.05 compared to WT control, # indicates
P < 0.05 compared to Mnk1-KO control and + indicates P < 0.05 compared to Mnk2-
KO control, n = 3. (C) as panel A but from PC3 cells treated with transfection reagent
alone or with Mnk1 or Mnk2 siRNA (as indicated from Western blots for Mnk1 and
Mnk2) for 48 h followed by overnight serum starvation and subsequent treatment
with 100 nM rapamycin or 0.5 lM PMA for 2 h. Samples of cell lysates were also
analysed by Western blot for Mnk1 (D) Graphical representation of data in panel C
i.e., the ratio of p-eIF4E/total eIF4E expressed either as % of that in each set of
untreated cells (left side) or % of that in untreated control cells (right side); bars are
coded as in Panel B. B and intensities were quantiﬁed using Licor Odyssey software.
Student’s t-test was used to analyse the data, ⁄indicates P < 0.05 compared to no
siRNA control, # indicates P < 0.05 compared to Mnk1 siRNA control and + indicates
P < 0.05 compared to Mnk2 siRNA control, n = 4.
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described previously [21]. For immunoprecipitation, cells were
lysed in 10 mM HEPES–KOH (pH 7.4), 50 mM NaF, 2 mM EDTA,
1% Triton X-100, 1 mM DTT, 0.5 mM Na3VO4,and 1 protease
inhibitor cocktail (Roche). 20 ll of Protein G beads (GE Healthcare)
per sample, were washed in lysis buffer and centrifuged at 8500g
for 30 s. The supernatant was removed and 300 lg of cell lysate
was added along with 1 lg HA antibody (Roche) and incubated
at 4 C for 1 h, then centrifuged as previously. Immunoprecipitates
of HA-tagged proteins were washed once in lysis buffer containing1 M LiCl and once with lysis buffer and once in kinase assay buffer
(20 mM HEPES–KOH, pH 7.5, 50 mM KCl, 2 mM MgCl2). 5 ll was
aliquoted and denatured in 20 ll 5 sample buffer.
Samples were subjected to SDS–PAGE as described [33] and
blots were incubated with antibodies overnight at 4 C. Antibodies
for eIF4E, phospho-eIF4E [Ser209], 4E-BP1 and phospho-Mnk were
from Cell Signaling Technology whilst anti-eIF4G was a kind gift
from Professor Simon Morley (Sussex).
The data shown are representative of at least three independent
experiments.
2.3. Mnk2 kinase activity assay
15 ll of HA immunoprecipitated Mnk2a was incubated in 30 ll
kinase buffer with 1 lg recombinant eIF4E, 100 lM ATP and
0.5 lCi [c-32P]ATP for 10 min at 30 C. The reaction was stopped
by adding 10 ll 5 sample buffer and denatured at 95 C for
5 min. Samples were analysed by SDS–PAGE and incorporated
radioactivity was assessed using a phosphoimager-screen and
developed with the Typhoon 700 imaging system. The data
shown are representative of three independent experiments.
3. Results
3.1. Rapamycin increases eIF4E phosphorylation in PC3 cells
PC3 cells were treated with rapamycin, lysed, and eIF4E was
isolated by afﬁnity puriﬁcation on 7-methyl GTP-Sepharose
(m7GTP-Sepharose). Samples of bound proteins were subjected to
SDS–PAGE and eIF4E phosphorylation was monitored by immuno-
blot using a phosphospeciﬁc antibody for p-Ser209 in eIF4E. Rapa-
mycin markedly enhanced the level of p-eIF4E (almost twofold;
Fig. 1A and B), in line with earlier data [28]. However, rapamycin
did not increase the low basal level of phosphorylation (activation)
of ERK (Fig. 1A), indicating that the increased phosphorylation of
eIF4E does not reﬂect the activation of ERK signalling upstream
of Mnk1.
eIF4G binds to the Mnks and this enhances their ability to phos-
phorylate eIF4E, which also binds to eIF4G [34]. The level eIF4E/
eIF4G binding may be a key determinant of the level of eIF4E phos-
phorylation. We therefore examined the amount of eIF4G co-puri-
fying with eIF4E on m7GTP-Sepharose (Fig. 1A and C). Surprisingly,
rapamycin did not decrease this, and indeed actually appeared to
increase the amount of eIF4G recovered on m7GTP-Sepharose
beads, but the increase was not statistically signiﬁcant. Rapamycin
also somewhat decreased the amount of 4E-BP1 co-purifying with
eIF4E. Since eIF4G and 4E-BP1 compete with one another for bind-
ing to a shared site of eIF4E, this observation is consistent with the
modest increase in bound eIF4G. The fact rapamycin did not in-
crease 4E-BP1 binding to eIF4E is consistent with other studies in
several cell-types (see e.g., [10,11,35]). In contrast, mTOR kinase
inhibitors do cause marked dephosphorylation of 4E-BP1 and
therefore decrease eIF4G/eIF4E binding. Thus, PP242 [10] caused
a strong increase in the binding of 4E-BP1 to eIF4E, a concomitant
loss of associated eIF4G, as well as a marked decrease in eIF4E
phosphorylation. These data are consistent with other studies
which show that compounds such as PP242 inhibit effects of
mTORC1 which are insensitive to rapamycin and thus have a much
greater effect on 4E-BP1 phosphorylation (e.g., [10,11,35]).3.2. Roles of Mnk1 and Mnk2 in the rapamycin-induced
phosphorylation of eIF4E
Although the increased binding of eIF4G to eIF4E caused by rap-
amycin may contribute to the enhanced phosphorylation of eIF4E,
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also play a role here. To address this, we ﬁrst turned to cells
(mouse embryonic ﬁbroblasts, MEFs) in which either Mnk1 or
Mnk2 has been genetically knocked out. (Mnk1/2 double knockout
cells are not of interest as eIF4E is not phosphorylated in them
[36]). Rapamycin increased the phosphorylation of eIF4E in wild-
type MEFs (Fig. 2A and B) and in Mnk1-KO cells (Fig. 2A and B)
but not in Mnk2-KO MEFs. (The basal level of p-eIF4E is lower in
the Mnk2-KO cells because basal phosphorylation of eIF4E is lar-
gely dependent upon Mnk2 [36]). Taken together, these data
strongly imply that the effect of rapamycin on eIF4E phosphoryla-
tion is mediated via Mnk2 rather than Mnk1.Fig. 3. Mnk2 activity increases in response to rapamycin treatment. (A) PC3 cells trans
PP242 for 2 h. After immunoprecipitation with anti-HA, an in vitro kinase assay was
undergoes phosphorylation in the assay, as indicated). The lower part shows Western b
representation of 32P incorporation into Mnk2a normalised to HA input. Bands were qua
software (Westerns), respectively, n = 4. (C) Graphical representation of p-Mnk2a norma
software. In B and C, Student’s t-test was used to analyse the data, ⁄indicates P < 0.05 com
mutant and treated with 100 nM rapamycin for 2 h. After HA immunoprecipitation, Mnk
blots of HA input and p-Mnk are shown below the main panel. (E) Graphical representat
Bands were quantiﬁed by densitometry using ImageJ and the Licor Odyssey software, res
to WT control, n = 4.To further conﬁrm this conclusion, we explored the effects of
siRNA-mediated knockdown of Mnk1 or Mnk2 in PC3 cells. siRNA
for Mnk1 decreased the levels of Mnk1 protein (Fig. 2C) but did not
eliminate it (despite attempts to improve its efﬁcacy). Since there
is no suitable antibody for Mnk2, we were unable to access the ex-
tent of knockdown by Western blot; however, siRNA for Mnk2 did
substantially decrease basal eIF4E phosphorylation, consistent
with the observation that Mnk2 is important for basal eIF4E phos-
phorylation [36] and indicating a substantial decrease in Mnk2 lev-
els in the siRNA-treated cells. Knocking downMnk2 appeared to be
associated with increased expression of Mnk1; the reason for this
is unknown.fected with a vector for HA-Mnk2a were treated with 100 nM rapamycin or 1 lM
performed for the activity of HA-Mnk2a against recombinant eIF4E (Mnk2a also
lots of HA immunoprecipitations using anti-HA and p-Mnk antisera. (B) Graphical
ntiﬁed by densitometry using ImageJ (phosphorimager data) and the Licor Odyssey
lised to HA input. Bands were quantiﬁed by densitometry using the Licor Odyssey
pared to control. (D) PC3 cells transfected with a vector for HA-Mnk2a or a S437A
activity was assayed; the ﬁgure shows an autoradiograph of the stained gel. Western
ion of 32P incorporation into Mnk2a or Mnk2a [Ser437Ala] normalised to HA input.
pectively. Student’s t-test was used to analyse the data, ⁄indicates P < 0.05 compared
Table 1
Sequences of human and mouse Mnk2a.
The residues whose phosphorylation was altered by rapamycin are highlighted in black and the MAP kinase-binding motif is highlighted in gray. The threonine residues in the
activation loop that are phosphorylated by MAP kinases are shown in capital letters.
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which was enhanced by rapamycin (Fig. 2C and D). Knockdown of
Mnk1 did not affect the basal phosphorylation of eIF4E or the abil-
ity of rapamycin to increase p-eIF4E levels. In contrast, knocking
downMnk2 greatly decreased basal p-eIF4E, which did not now in-
crease in response to rapamycin. These data are again consistent
with the known properties of Mnk1 and Mnk2 and support the
conclusion that the effect of rapamycin requires Mnk2.
The differing magnitudes of the effects of rapamycin on eIF4E
phosphorylation in PC3 cells and MEFs may reﬂect differing levels
of the distinct Mnk isoforms in these cells (including, perhaps, the
existence of the shorter Mnk1b and Mnk2b isoforms in human
cells; such isoforms are not known to occur in mouse). Given the
different origin and species of these cells, other differences may
also contribute to this.
3.3. Rapamycin treatment of cells increases the activity of Mnk2a
Because of the ability of rapamycin to increase the phosphory-
lation of eIF4E requires Mnk2a, but not Mnk1, we tested whether
rapamycin treatment activated Mnk2a. PC3 cells were transfected
with a vector encoding HA-tagged Mnk2a and in some cases trea-
ted with rapamycin or PP242. After lysis, HA-Mnk2a was immuno-
precipitated and its activity assayed against recombinant eIF4E
(Fig. 3A and B). Rapamycin markedly enhanced the activity of
Mnk2a both in autophosphorylation and against eIF4E. PP242
treatment also enhanced Mnk2a activity. However, rapamycin
did not alter the level of phosphorylation of the activation loop
sites as detected by a speciﬁc anti-phospho-Mnk antibody
(Fig. 3A and C). Thus, rapamycin enhances Mnk2a activity indepen-
dently of changes in T-loop phosphorylation. Consistent with this,
rapamycin did not affect Mnk2a/p-ERK binding (data not shown).
To study the mechanism by which rapamycin affects Mnk2a
activity, we subjected samples of Mnk2a from control or rapamy-
cin-treated cells to mass spectrometric analysis. This revealed
changes in the phosphorylation of two residues, Ser74 and
Ser437 (data not shown) both of which are conserved in human
and mouse Mnk2 (Table 1).
We therefore created mutants in which Ser74 or Ser437 was
changed to alanine and examined the effects of rapamycin onMnk2a[S74A] and Mnk2a[S437A] in parallel with wildtype Mnk2a.
Mnk2a[S74A] phosphorylation was still increased in response to
rapamycin (data not shown) while Mnk2a[S437A] showed higher
basal activity, in autophosphorylation and against eIF4E than WT
Mnk2a, and this was not increased by rapamycin (Fig. 3D and E).
For these assays, Mnk2a was immunoprecipitated under condi-
tions where it dissociates from eIF4G so that alterations in this
parameter may be excluded [19]. The data show that S437 plays
a key role in the effects of rapamycin on Mnk2a activity, being suf-
ﬁcient to explain the observed changes in Mnk2a activity.
4. Conclusions
Rapamycin-induced activation of Mnk2a is dependent upon a
conserved serine residue (Ser437), which was ﬁrst identiﬁed, but
not characterized, in an earlier study [21]. Our ﬁndings are consis-
tent with a model where Ser437 is basally phosphorylated and rap-
amycin represses this, eliciting activation of Mnk2a. Although this
is next to the MAP kinase-binding motif, it seems that changes
Mnk2a activity are not due to alterations in the phosphorylation
of the T-loop by ERK, since rapamycin does not affect T-loop phos-
phorylation. Our earlier data showed that this C-terminal region of
Mnk2a affects accessibility to the N-terminal region of the protein
[19]. Phosphorylation of Ser437 may thus alter the overall confor-
mation of Mnk2a leading to higher intrinsic activity.
Our data contrast with earlier ﬁndings [25] who reported that
rapamycin still increased eIF4E phosphorylation in Mnk2-KO cells.
The reasons for this discrepancy are unclear.
In terms of the application of rapalogs in anti-cancer therapy, it
will be important to establish whether speciﬁc tumours express
Mnk2, Mnk1 or both. Rapamycin is likely to increase the phosphor-
ylation of eIF4E in tumours expressing Mnk2, but not where Mnk1
is the major isoform.
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